| Literature DB >> 9795386 |
K E Ugen1, S B Nyland, J D Boyer, C Vidal, L Lera, S Rasheid, M Chattergoon, M L Bagarazzi, R Ciccarelli, T Higgins, Y Baine, R Ginsberg, R R Macgregor, D B Weiner.
Abstract
Humoral and cellular immune responses have been produced by intramuscular vaccination with DNA plasmids expressing HIV-1 genes, suggesting possible immunotherapeutic and prophylactic value for these constructs. Vaccination with these constructs has decreased HIV-1 viral load in HIV-1-infected chimpanzees. In addition, naive (i.e. non-HIV-1-infected) chimpanzees were protected against a heterologous challenge with HIV-1. Ongoing phase I clinical trials show that therapeutic vaccinations indeed boost anti-HIV-1 immune responses in humans. A therapeutic phase I trial on humans with these constructs induced a good safety profile and also demonstrated an immunological potentiation. These findings indicate that further studies with these constructs in humans are warranted.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9795386 DOI： 10.1016/s0264-410x(98)00180-7
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641